ArticleInfection and drug resistance2026
Severe Fever with Thrombocytopenia Syndrome Complicated by Mixed Pulmonary Aspergillus and Mucorales Infection and Isavuconazole-Associated Liver Injury: A Case Report.
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe fever with thrombocytopenia syndrome (SFTS) is a tick-borne viral disease characterized by severe immune dysregulation and high mortality, predisposing patients to opportunistic infections. Case Presentation: We report a 76-year-old male patient diagnosed with SFTS complicated by chronic hepatitis B with low-level viral replication, liver injury, and myocardial injury. After initial treatment with intravenous immunoglobulin, hepatoprotective therapy, and antiviral therapy, the patient stabilized. During hospitalization, he developed pulmonary infection. Sputum culture was positive for Aspergillus fumigatus and serum galactomannan (GM) test was positive. Initial treatment with voriconazole led to radiological improvement in the right lung lesion; however, progression of the left lung lesion was observed. Bronchoalveolar lavage fluid metagenomic next-generation sequencing (mNGS) identified Rhizopus microsporus, leading to the diagnosis of invasive pulmonary Aspergillus-Mucorales coinfection. Oral isavuconazole combined with nebulized amphotericin B was administered, resulting in significant clinical and radiological improvement. Approximately one month after isavuconazole therapy, the patient developed jaundice and coagulation dysfunction. After exclusion of hepatitis B virus reactivation and other potential causes, isavuconazole-associated drug-induced liver injury was considered probable based on the clinical course and a RUCAM score of 8. Conclusion: SFTS patients are highly susceptible to invasive fungal infections due to immune dysregulation, thrombocytopenia, and endothelial injury. Clinicians should consider mucormycosis in patients with poor response to voriconazole and progressive pulmonary lesions, and early bronchoscopy with mNGS is recommended. Although isavuconazole is considered relatively safe, liver function monitoring is essential, especially in patients with underlying liver disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.